Bioton

Diabetes Pharmaceuticalsbioton.com

Company typePrivate
Founded1989
HeadquartersOzarow Mazowiecki, Poland
Headcount251–500
GTM typeB2C
OfferingHardware or Manufacturing

Bioton firmographics

Firmographics

Name: Bioton
Legal name: BIOTON S.A.
Website: https://bioton.com
Company type: Private
Founded year: 1989
Operating status: Operating
Headcount range: 251–500 employees
Ownership category
akta.pro rank

Bioton industry classification

Industry

Product category: Diabetes Pharmaceuticals
NAICS: Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)
SIC: Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry: Insulin & Analog Biosimilars (HLAAAHAD)
akta.pro secondary industries: Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Packaging, Labeling & Serialization Services (biologics/cold chain) (HLAAAKAJ)

Keywords

Biosynthetic insulin
Diabetes pharmaceuticals
Insulin injection devices
Biotech drug manufacturing
Diabetology solutions

Where Bioton is headquartered

Location

Headquarters

HQ city: Ozarow Mazowiecki
HQ country: Poland
HQ region: Europe

Offices1 record

Markets served

Bioton business model

Business model

GTM type: B2C
Offering type: Hardware or Manufacturing
Cost components: Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Distribution channels2 records

Marketing channels2 records

Bioton product offering

Product offering

Core offering

Bioton is a Polish biotechnological pharmaceutical company that manufactures and sells biosynthetic insulin products (Gensulin M30, Gensulin N, Gensulin R in 100 IU formulations) and the GensuPen automatic insulin injection device for diabetes treatment. The company operates its own GMP-compliant manufacturing facility in Macierzysz near Warsaw, handling the full insulin production cycle, and supports products with a direct patient education platform.

Product overview

Bioton is a pharmaceutical company offering complete diabetological solutions. Its product portfolio centers on insulin products (Gensulin) and an automatic injection device (GensuPen), supported by patient education services through the 'Zapytaj Specjalistę' platform. The company operates its own manufacturing facility in Macierzysz near Warsaw, where insulin synthesis and production take place.

Differentiator

Problem solved

Functional benefit

Brands

Gensulin: Insulin product line including Gensulin M30, Gensulin N, and Gensulin R for diabetes treatment
GensuPen
Bioton Marketing Agency
Biolek

Products and services

Gensulin

Companies that use Bioton

Customer profile

Segments2 records

Ideal customer profiles2 records

Bioton technology and API

Technology

Technology focussed No

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Bioton partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Bioton competitors and assessment

Company assessment

Broad incumbents

Sanofi: Major insulin producer (Lantus, Toujeo, Apidra) with global diabetes commercial reach. Comparable to Bioton in the insulin manufacturing category, but Sanofi spans vaccines, rare disease, and immunology, making Bioton's pure-play diabetes focus a clear differentiation lens.
Novo Nordisk: Global leader in insulin and diabetes care with a full analog insulin portfolio (NovoRapid, Levemir, Tresiba) and the dominant GLP-1 franchise (Ozempic). Comparable to Bioton as a vertically integrated insulin manufacturer, but operating at vastly greater scale and breadth across diabetes and obesity therapeutics.
Eli Lilly: Manufacturer of Humalog, Humulin, and the new generation of diabetes/obesity therapies (Mounjaro, Zepbound). Comparable to Bioton as an insulin originator/biomanufacturer, with a vastly larger and more diversified therapeutic footprint.

Direct peers

Biocon: India-based biopharmaceutical company with a leading global biosimilar insulin and analog franchise (Semglee, Insulin Glargine). The closest direct comparator to Bioton as a non-originator insulin biosimilar manufacturer competing in regulated markets, with a similarly integrated biologics manufacturing footprint.
Tonghua Dongbao Pharmaceutical: China's largest insulin producer, focused on recombinant human insulin and insulin analogs. Comparable to Bioton as a dedicated insulin manufacturer with vertically integrated fermentation and fill-finish capability targeting emerging and regulated export markets.
Gan & Lee Pharmaceuticals: Chinese insulin specialist producing insulin analogs (insulin glargine, lispro, aspart) and recombinant human insulin. Comparable to Bioton as an insulin-focused biomanufacturer with growing international registration ambitions and a portfolio bundled with injection devices.

Others

Ypsomed: Swiss manufacturer of injection and infusion systems, including insulin pen platforms used by multiple insulin producers. Comparable to Bioton as a supplier of the pen-style delivery hardware (analogous to GensuPen) that complements biologic insulin franchises.

Emerging players

Adocia: French clinical-stage biotech developing novel insulin formulations (e.g., BioChaperone insulin combinations) and partnered programs with global pharma. Comparable to Bioton as a diabetes-focused biotech, though Adocia operates upstream in formulation R&D rather than commercial manufacturing.
Wockhardt: India-based pharmaceutical company with a dedicated insulin and biosimilars business supplying emerging markets. Comparable to Bioton as a non-originator insulin producer targeting cost-sensitive geographies with human insulin and biosimilar formulations.

Regional players

Polpharma: Poland's largest pharmaceutical manufacturer and one of the leading generic producers in Central Europe. Comparable to Bioton as a domestic Polish pharma peer competing for HCP relationships, distribution channels, and government procurement, though Polpharma is broader in therapeutic scope and not insulin-specialized.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Bioton financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioton leadership team

Management profile

Number of profiles

Bioton funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioton M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioton

What does Bioton do?

Is Bioton a public or private company?

Bioton is a private company. It is classified as private equity controlled and is currently operating.

When was Bioton founded?

Bioton was founded in 1989. It employs 251 to 500 people.

Where is Bioton based?

Bioton is headquartered in Ozarow Mazowiecki, Poland, in the Europe region.

Who are Bioton's main competitors?

Broad incumbents on record are Sanofi, Novo Nordisk and Eli Lilly. Direct peers are Biocon, Tonghua Dongbao Pharmaceutical and Gan & Lee Pharmaceuticals. Ypsomed is listed as an others. Emerging players are Adocia and Wockhardt. Polpharma is listed as a regional player.

Does Bioton have an API?

No public API is recorded for Bioton.

What industry is Bioton in?

Bioton's product category is Diabetes Pharmaceuticals. Its primary akta.pro industry code is HLAAAHAD, Insulin & Analog Biosimilars, with a secondary code of HLAAAKAA, Biologic API/Drug Substance Manufacturing Services. Its NAICS code is 325414 and its SIC code is 2834.